{"id":12301,"date":"2008-06-07T01:30:00","date_gmt":"2008-06-06T23:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/copie-di-farmaci-biotech-simili-ma-non-identiche-alle-molecole-originatrici\/"},"modified":"2008-06-07T01:30:00","modified_gmt":"2008-06-06T23:30:00","slug":"copie-di-farmaci-biotech-simili-ma-non-identiche-alle-molecole-originatrici","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/copie-di-farmaci-biotech-simili-ma-non-identiche-alle-molecole-originatrici\/","title":{"rendered":"COPIES OF BIOTECH DRUGS SIMILAR BUT NOT IDENTICAL TO THE ORIGINAL MOLECULES"},"content":{"rendered":"<p>&nbsp;<br \/> ROME \u2013 When asked whether biosimilars, i.e. the genetic versions of biotech drugs, can be the same as the &quot;designer&quot; molecule as happens with equivalent drugs, 3 out of 10 oncologists are unable to answer and 2 out of 10 think, wrongly, that there is identity with the parent molecule. It is the result, presented in Rome during a conference held at the Regina Elena Institute, of a survey carried out by the Aiom Foundation (medical oncology) on 700 Italian specialists. A delicate topic, which now concerns 40 percent of the drugs used in oncology: when patents expire, attempts are made to reproduce biotech molecules but the copies are not always the same as the model. \u00abBiosimilars are not like their equivalents - explains Francesco Cognetti of the Regina Elena in Rome - France and Spain have prohibited the automatic replacement of a biological drug with a biosimilar on the basis of the fact that copying and synthesizing therapeutic proteins starting from living material is not how to copy acetylsalicylic acid: <strong>recently the EMEA denied authorization to the biosimilar of interferon alfa 2a\u00bb.<\/strong> So far, two biosimilars (somatotropin and Epo) have been approved in Europe, but only in some countries: but will Italian health authorities also be able to order these molecules? The Tar, December 2007, says no.<br \/> Medical Courier of 05\/06\/2008 N. 17 29 MAY 2008&nbsp;&nbsp;&nbsp; <\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp; ROMA &#8211; Alla domanda se i biosimilari, ovvero le versioni genetiche dei farmaci biotech, possano essere uguali alla molecola &quot;griffata&quot; cosi come accade per i farmaci equivalenti, 3 oncologi su 10 non sanno rispondere e 2 su 10 pensano, sbagliando, che vi sia identit&agrave; con la molecola d&#8217;origine. E&#8217; il risultato, presentato a Roma &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12301","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12301"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12301\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}